Cosmo NV (CMOPF)
69.00
-0.50
(-0.72%)
USD |
OTCM |
Sep 02, 16:00
Cosmo Research and Development Expense (Annual) : 36.21M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 36.21M |
| December 31, 2024 | 41.14M |
| December 31, 2023 | 27.72M |
| December 31, 2022 | 12.13M |
| December 31, 2021 | 8.978M |
| December 31, 2020 | 15.50M |
| December 31, 2019 | 16.97M |
| December 31, 2018 | 12.30M |
| December 31, 2017 | 10.21M |
| Date | Value |
|---|---|
| December 31, 2016 | 9.134M |
| December 31, 2015 | 25.60M |
| December 31, 2014 | 25.49M |
| December 31, 2013 | 23.37M |
| December 31, 2012 | 14.02M |
| December 31, 2011 | 7.194M |
| December 31, 2010 | 4.518M |
| December 31, 2009 | 6.193M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Avadel Pharmaceuticals Plc | -- |
| Jazz Pharmaceuticals Plc | 782.74M |
| Perrigo Co. Plc | 95.40M |
| GH Research Plc | 38.73M |
| Alkermes Plc | 318.36M |